Meeting News

MRI studies show evidence of CAR-T neurotoxicity after clinical symptoms resolve

December 7, 2019
ORLANDO — Younger patients who receive chimeric antigen receptor T-cell therapy for B-cell acute lymphoblastic leukemia may develop brain…

In the Journals

Children, young adults experience ‘rapid improvement’ in quality of life after CAR-T for ALL

December 6, 2019
Children and young adults with relapsed or refractory B-cell acute lymphoblastic leukemia reported sustained, clinically meaningful improvement in…

In the JournalsPerspective

UM171-expanded cord blood safe for certain adults with hematologic malignancies

December 3, 2019
Single UM171-expanded cord blood transplantation appeared safe and feasible among a small cohort of patients with hematologic malignancies who lacked…

Partnership funds research to assess connection between cancer, aging

December 2, 2019
The Partnership for Aging and Cancer Research Program awarded seven grants intended to fund research into the link between aging and cancer. The…

Trend Watch

UCLA Opens Clinical Trial of Bispecific CAR T-cell Therapy for Advanced Lymphoma, Leukemia

Cell Therapy Next, November/December 2019
The UCLA Jonsson Cancer Center has begun enrolling patients in its latest chimeric antigen receptor T-cell immunotherapy trial for patients with…

Clinical Trials Snapshot

Study of huCART19 for Very High-Risk (VHR) Subsets of Pediatric B-ALL

Cell Therapy Next, November/December 2019
Phase 2 study to evaluate humanized CD19 redirected autologous T cells (or huCART19 cells) in pediatric patients with CD19 expressing relapsed and…

Clinical Trials Snapshot

Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma

Cell Therapy Next, November/December 2019
Phase 1, single center, open-label study to establish a safe dose (ie, number of cells/kg) of autologous iC9.GD2.CAR.IL-15 T-cells in pediatric…

Clinical Trials Update

Specific Peptide-Enhanced Affinity Receptor MAGE-A4 T Cells for Synovial Sarcoma

Cell Therapy Next, November/December 2019
Soft tissue sarcoma is a rare type of cancer that affects the body’s soft tissues, such as muscles, fat and ligaments. There are more than 50…

Clinical Trials Snapshot

Her2 Chimeric Antigen Receptor Expressing T Cells in Advanced Sarcoma

Cell Therapy Next, November/December 2019
Phase 1, interventional, open-label study to determine the largest safe dose of chimeric T cells for patients with sarcoma, and to determine the…

Cover Story

Near the Nation’s Capital Lies a ‘House of Hope’

Cell Therapy Next, November/December 2019
Chimeric antigen receptor T-cell therapies have been approved by the FDA for two indications thus far, with a third for multiple myeloma expected…

Clinical Trials Snapshot

Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Patients With Pediatric Solid Tumors (GAP)

Cell Therapy Next, November/December 2019
Phase 1, interventional, open-label study of GAP T cells for patients with GPC3-positive liver cancers.

Clinical Trials Snapshot

CD22 Redirected Autologous T Cells for ALL

Cell Therapy Next, November/December 2019
Phase 1, single center, single arm, open-label pilot study to determine the feasibility and safety of a single dose administered as spilt fractions…

In the JournalsPerspective

Adjuvant Cytokine-Induced Killer Cell Therapy Improves Survival in Postoperative Breast Cancer

Cell Therapy Next, November/December 2019
An analysis of patients with postoperative breast cancer has shown increased OS and RFS among patients who received adjuvant therapy with…

Meeting News

Genetic biomarkers predict long-term OS for adoptive cell therapy in metastatic melanoma

November 22, 2019
NATIONAL HARBOR, Md. — Certain genetic biomarkers predicted long-term overall survival for patients who received adoptive cell therapy with…

In the JournalsPerspective

Propensity score analysis supports blinatumomab vs. standard of care for relapsed/refractory ALL subset

November 20, 2019
Blinatumomab appeared to confer better outcomes than standard of care among adults with relapsed or refractory Philadelphia chromosome-positive acute…

Meeting News

Urinary microbiome variations associated with response to BCG therapy for bladder cancer

November 19, 2019
There is an association between certain types of commensal urinary microbiome bacteria found in the urinary tract and a clinical response to bacillus…

NIH selects five Lasker Clinical Research Scholars

November 16, 2019
The NIH selected five scientists as Lasker Clinical Research Scholars. The competitive program — part of a joint initiative with Albert and…

Meeting NewsPerspective

Autologous antigen-loaded vaccine safe, feasible for neuroblastoma

November 9, 2019
NATIONAL HARBOR, Md. — An investigational vaccine of autologous dendritic cells loaded with autologous tumor antigens was safe and feasible as…

Meeting News

Off-the-shelf natural killer cells safe, clinically active for advanced Merkel cell carcinoma

November 8, 2019
NATIONAL HARBOR, Md. — Allogeneic activated natural killer cell therapy resulted in some antitumor activity with no serious side effects in…

FDA News

FDA restructures, renames office that reviews cancer therapies

November 6, 2019
The FDA office that reviews applications for cancer therapies has been renamed and reorganized. The Center for Drug Evaluation and Research’s…